Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02794571 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
A Phase 1 study of Advanced/Metastatic Tumors, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 518
- Enrollment target
- 20
- Study locations
NCT02794571 is a Phase 1 study of Advanced/Metastatic Tumors that has completed, run by Genentech. The registered enrollment target is 518 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02794571, a Phase 1 study of Advanced/Metastatic Tumors, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 518 participants
- Enrollment target
- 20
- Study locations
Study Summary
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Tiragolumab
Study Locations (20)
Other
- Institut Bergonie CLCC Bordeaux - Bordeaux
- Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes - Lyon
- Institut Curie - Paris
- Institut Claudius Regaud; Departement Oncologie Medicale - Toulouse
- Institut Gustave Roussy - Villejuif
- National Cancer Center Hospital - Tokyo
- The Cancer Institute Hospital of Japanese Foundation For Cancer Research - Tokyo
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
Arizona
- Honor Health Research Institute - Scottsdale
California
- University of California Los Angeles - Santa Monica
Connecticut
- Yale Cancer Center - New Haven
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Henry Ford Hospital - Detroit
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2016-05-23 |
| Est. Completion | 2024-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02794571
The ClinicalTrials.gov registry entry for NCT02794571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced/Metastatic Tumors appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT02794571 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT02794571 about?
NCT02794571 is a clinical study titled "Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors". This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incura...
What is the current status of trial NCT02794571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 518 participants. The study started on 2016-05-23. Estimated completion is 2024-11-13.
What conditions does trial NCT02794571 study?
This clinical trial studies the following conditions: Advanced/Metastatic Tumors.
What interventions are being tested in trial NCT02794571?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT02794571?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02794571 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.